Humacyte Financial Statements From 2010 to 2024

HUMA Stock  USD 4.51  0.14  3.01%   
Humacyte financial statements provide useful quarterly and yearly information to potential Humacyte investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Humacyte financial statements helps investors assess Humacyte's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Humacyte's valuation are summarized below:
Gross Profit
1.6 M
Market Capitalization
598.3 M
Earnings Share
(1.34)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trends for Humacyte, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Humacyte regular market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Enterprise Value is expected to grow to about 284.9 M, whereas Market Cap is forecasted to decline to about 179.5 M.

Humacyte Total Revenue

0.0

Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.

Humacyte Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets196.8 M128.2 M174 M
Pretty Stable
Short and Long Term Debt Total45.9 M58.1 M32.4 M
Slightly volatile
Other Current Liabilities7.2 M6.7 M7.2 M
Slightly volatile
Total Current Liabilities15.7 M18.4 M12.3 M
Slightly volatile
Property Plant And Equipment Net46.6 M44.9 M66.8 M
Slightly volatile
Accounts Payable3.5 M6.5 M3.2 M
Very volatile
Cash127.9 M80.4 M103.5 M
Slightly volatile
Non Current Assets Total46.6 M44.9 M66.8 M
Slightly volatile
Cash And Short Term Investments130.1 M80.4 M104.3 M
Slightly volatile
Common Stock Shares Outstanding61.4 M103.4 M34.8 M
Slightly volatile
Liabilities And Stockholders Equity196.8 M128.2 M174 M
Pretty Stable
Non Current Liabilities Total126.2 M96.2 M76.4 M
Slightly volatile
Other Current Assets2.9 M2.8 M1.5 M
Slightly volatile
Other Stockholder Equity374.3 M550.9 M158.1 M
Slightly volatile
Total Liabilities137.6 M114.7 M88.4 M
Slightly volatile
Total Current Assets132.7 M83.3 M106 M
Slightly volatile
Common Stock9.5 K10 K72 M
Slightly volatile
Property Plant Equipment40.8 M27 M62.4 M
Slightly volatile
Other Liabilities48.8 M32.2 M14.4 M
Slightly volatile
Warrants70.4 M79.2 M86.3 M
Slightly volatile
Long Term Debt24 M38.6 MM
Slightly volatile
Common Stock Total Equity8.6 KK69.1 M
Slightly volatile
Capital Surpluse397.4 M625 M142.8 M
Slightly volatile
Capital Lease Obligations17.5 M18.9 M24.1 M
Slightly volatile
Long Term Investments80 M90 M98 M
Slightly volatile
Property Plant And Equipment Gross52.6 M76.3 M74 M
Slightly volatile
Short and Long Term Debt6.1 M9.9 MM
Slightly volatile
Capital Stock8.5 K11.5 K3.4 K
Slightly volatile
Non Current Liabilities Other60.5 M38.7 M24 M
Slightly volatile
Net Working Capital123.2 M64.8 M58.2 M
Slightly volatile
Short Term Debt6.1 M5.2 M4.7 M
Slightly volatile
Long Term Debt Total19.1 M18.3 M25.7 M
Slightly volatile

Humacyte Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.7 M7.7 M7.3 M
Slightly volatile
Interest Expense1.1 M1.1 M2.5 M
Pretty Stable
Selling General Administrative21.1 M23.4 M17.5 M
Slightly volatile
Other Operating Expenses92.9 M100 M89.5 M
Pretty Stable
Research Development72.8 M76.5 M72.3 M
Slightly volatile
Cost Of Revenue80.4 M76.5 M62 M
Slightly volatile
Total Operating Expenses22.3 M23.5 M29.3 M
Slightly volatile
Interest IncomeM5.7 M1.2 M
Slightly volatile
Reconciled Depreciation6.6 MM8.2 M
Slightly volatile
Non Operating Income Net Other75.8 M90.6 M63.6 M
Slightly volatile
Selling And Marketing Expenses2.4 M2.7 M2.9 M
Slightly volatile

Humacyte Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.1 M6.8 M5.3 M
Slightly volatile
Begin Period Cash Flow148.4 M149.8 M159.1 M
Slightly volatile
Other Cashflows From Financing Activities61.5 M38.6 M23.5 M
Slightly volatile
Depreciation8.6 M7.7 M7.2 M
Slightly volatile
Capital Expenditures1.9 M2.3 M5.8 M
Slightly volatile
End Period Cash Flow128 M80.8 M103.5 M
Slightly volatile
Sale Purchase Of Stock457.4 K481.5 K194.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio96.9512565.9839
Slightly volatile
Days Sales Outstanding7.98.3130.4349
Slightly volatile
Stock Based Compensation To Revenue3.173.561.9378
Slightly volatile
Capex To Depreciation0.370.29540.8598
Slightly volatile
EV To Sales53.4666.3838.077
Slightly volatile
Payables Turnover9.6411.795117.4268
Slightly volatile
Sales General And Administrative To Revenue8.4113.165.8189
Slightly volatile
Research And Ddevelopement To Revenue27.536.3820.7557
Slightly volatile
Capex To Revenue0.650.771.0406
Slightly volatile
Cash Per Share0.740.77793.8945
Slightly volatile
Days Payables Outstanding29.430.94511.1 K
Pretty Stable
Income Quality0.630.66171.3028
Slightly volatile
Current Ratio4.294.51548.5804
Pretty Stable
Receivables Turnover47.7145.4417.7967
Slightly volatile
Graham Number1.691.776721.6761
Slightly volatile
Capex Per Share0.02090.0220.2748
Slightly volatile
Revenue Per Share0.01660.01750.2184
Slightly volatile
Interest Debt Per Share0.340.40940.231
Slightly volatile
Debt To Assets0.340.32140.0824
Slightly volatile
Operating Cycle6.46.7430.1394
Slightly volatile
Days Of Payables Outstanding29.430.94511.1 K
Pretty Stable
Ebt Per Ebit0.791.10720.8909
Slightly volatile
Quick Ratio4.294.51548.5805
Pretty Stable
Cash Ratio4.144.3628.3883
Pretty Stable
Days Of Sales Outstanding7.98.3130.4349
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.03111.0877
Slightly volatile
Fixed Asset Turnover0.0440.03590.0663
Slightly volatile
Debt Ratio0.340.32140.0824
Slightly volatile
Price Sales Ratio96.9512565.9839
Slightly volatile
Asset Turnover0.01730.00880.0279
Slightly volatile

Humacyte Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap179.5 M293.7 M203.5 M
Slightly volatile
Enterprise Value284.9 M271.4 M144.9 M
Slightly volatile

Humacyte Fundamental Market Drivers

Cash And Short Term Investments80.4 M

Humacyte Upcoming Events

22nd of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Humacyte Financial Statements

Humacyte stakeholders use historical fundamental indicators, such as Humacyte's revenue or net income, to determine how well the company is positioned to perform in the future. Although Humacyte investors may analyze each financial statement separately, they are all interrelated. For example, changes in Humacyte's assets and liabilities are reflected in the revenues and expenses on Humacyte's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.4 M-2.2 M
Cost Of Revenue76.5 M80.4 M
Stock Based Compensation To Revenue 3.56  3.17 
Sales General And Administrative To Revenue 13.16  8.41 
Research And Ddevelopement To Revenue 36.38  27.50 
Capex To Revenue 0.77  0.65 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(62.15)(65.26)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:
Check out the analysis of Humacyte Correlation against competitors.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.53)
Return On Equity
(8.51)
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.